Mylan to pay $465 million over EpiPen Medicaid rebate dispute
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Mylan (MYL) Sued by Shareholder Over EpiPen Payments
October 11, 2016 12:12 PM EDTMylan (NASDAQ: MYL) shares are on watch after an investor sued the company over allegations that it made misstatements on payments made to government health-insurance programs with respect to its EpiPen product, according to Bloomberg.
The lawsuit was filed in Manhattan court Tuesday.
Shares of Mylan are down around 1 percent.
... MoreMylan's (MYL) EpiPen Settlement with U.S. DOJ Seen as 'Significant' by BTIG; 'Buy' Rating Affirmed
October 10, 2016 7:39 AM EDTBTIG affirms Mylan N.V. (Nasdaq: MYL) at Buy with a price target of $55 after the company announced that its subsidiary, Mylan Inc., has agreed to the terms of a $465 million settlement with the U.S. Department of Justice and other government agencies... More
Raymond James Upgrades Mylan (MYL) to Strong Buy
October 10, 2016 7:32 AM EDTRaymond James upgraded Mylan (NASDAQ: MYL) from Market Perform to Strong Buy with a price target of $57.00.
For an analyst ratings summary and ratings history on Mylan click here. For more ratings news on Mylan click here.
Shares of Mylan closed at $35.94 yesterday.
... More